IBA Déclaration Intermédiaire – Premier Trimestre 2021

NEXT STORY
OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021
PREV STORY
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Churchill, Emergent BioSolutions, and Verus International and Encourages Investors to Contact the Firm
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19

author_avatar
NASDAQ Market News

Five Prime Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...

author_avatar
NASDAQ Market News

Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock

SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the ...

author_avatar
NASDAQ Market News